Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies.

Abstract Large B-cell lymphoma (LBCL) is curable with standard chemo-immunotherapy in the majority of cases. However, patients with primary refractory or relapsed disease have historically had limited treatment options. Two gene-modified chimeric antigen receptor (CAR) T-cell therapies have now been approved for these indications. The clinical decisions and management surrounding these gene-modified ‘living drugs’ are nuanced and complex. In this article, we discuss the evolving evidence supporting the use of these CAR T cells, including patient selection, screening procedures, special populations, bridging therapy, lymphodepletion, clinical management, relapse, and follow up.